The ultimate insult is Biocryst's market cap is in spitting distance of ours.
They with net cash of $11 million.
It's interesting they are in a similar predicament with their Phase 3 ready Gout program as to our Vapendavir.
A comment from their annual report "Due to the cost of future development and commercialization, we do not plan to initiate Phase 3 development of ulodesine without a partner."
This could very well be RP's exact words at the end of the year.
stale bull, page-4
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)